XML 63 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 01, 2024
Dec. 20, 2023
Aug. 01, 2023
Aug. 27, 2018
Jul. 31, 2022
Apr. 30, 2022
May 31, 2020
Apr. 30, 2020
Oct. 31, 2019
Jul. 31, 2019
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Aug. 31, 2023
Apr. 04, 2022
Loss Contingencies [Line Items]                                    
Cash consideration     $ 16,792,037                              
Options to acquire shares           144,191                      
Weighted exercise price           $ 10.71                        
Warrants to purchase shares           4,424                        
Exercise price           $ 7.32                        
Expiration date           Apr. 22, 2031                        
Payments receive     893,000                              
cash                     $ 3,000,000.0     $ 3,000,000.0     $ 693,000  
Cash consideration         $ 10,000,000.0                          
Number of shares         486,145                          
Cash Closing Consideration [Member]                                    
Loss Contingencies [Line Items]                                    
Purchase price     $ 15,250,000                              
Common Stock [Member]                                    
Loss Contingencies [Line Items]                                    
Warrants to purchase shares           12,301                        
Exercise price           $ 12.05                        
Expiration date           Aug. 10, 2030                        
Number of shares isssued                         26,143          
Precision Healing Inc [Member]                                    
Loss Contingencies [Line Items]                                    
Cash consideration           $ 125,966                        
Payments receive           $ 10,000,000.0                        
Precision Healing [Member]                                    
Loss Contingencies [Line Items]                                    
Payments receive               $ 10,000,000.0                    
Rochal [Member]                                    
Loss Contingencies [Line Items]                                    
Payment of cash             $ 500,000                      
Accredited Investors [Member]                                    
Loss Contingencies [Line Items]                                    
Issuance of shares           165,738                        
Nonaccredited Investors [Member]                                    
Loss Contingencies [Line Items]                                    
Share price                                   $ 30.75
Precision Healing [Member]                                    
Loss Contingencies [Line Items]                                    
Payment in cash           $ 600,000                        
Share price           $ 27.13   $ 27.13                    
Cost of Sales [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty expense                     0 $ 548,430   0 $ 1,069,244      
Sub License Agreement [Member]                                    
Loss Contingencies [Line Items]                                    
License agreement and royalties description       In August 2018, the Company entered an exclusive, world-wide sublicense agreement with CGI Cellerate RX, LLC (“CGI Cellerate RX”) to distribute certain hydrolyzed collagen products, including CellerateRX Surgical, into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the Company paid royalties of 3-5% of annual collected net sales of these products. As amended in January 2021, the term of the sublicense was extended through May 2050, with automatic successive year-to-year renewal terms thereafter so long as the Company’s Net Sales (as defined in the Sublicense Agreement) each year are equal to or in excess of $1,000,000. If the Company’s Net Sales fall below $1,000,000 for any year after the expiration date, CGI Cellerate RX has the right to terminate the Sublicense Agreement upon written notice.                            
BIAKOS License Agreement [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty expense                     $ 42,305 $ 32,500   $ 77,305 $ 65,000      
Royalty annual minimum percentage                           10.00%        
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Minimum [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty percentage                   2.00%                
Maximum amount of royalty                               $ 133,000    
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty percentage                   4.00%                
Maximum amount of royalty                           $ 150,000        
BIAKOS Agreement [Member] | Maximum [Member]                                    
Loss Contingencies [Line Items]                                    
Payment for additional royalties                           $ 1,000,000        
ABF License Agreement [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty annual minimum percentage                           10.00%        
ABF License Agreement [Member] | Minimum [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty percentage                 2.00%                  
Maximum amount of royalty                           $ 50,000        
ABF License Agreement [Member] | Maximum [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty percentage                 4.00%                  
Maximum amount of royalty                           75,000        
Payment for additional royalties                           $ 500,000        
Debrider License Agreement [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty annual minimum percentage                           10.00%        
Payment of cash             $ 1,000,000                      
Debrider License Agreement [Member] | Minimum [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty percentage             2.00%                      
Debrider License Agreement [Member] | Maximum [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty percentage             4.00%                      
Maximum amount of royalty                           $ 150,000        
Payment for additional royalties                           $ 1,000,000        
Purchase Agreement [Member]                                    
Loss Contingencies [Line Items]                                    
Acquisition consideration transferred         $ 7,600,000                          
cash         $ 1,600,000                          
Issuance of common stock for purchase of assets         291,686                          
Number of shares isssued         94,798                          
Purchase price         $ 7,600,000                          
Services Agreement [Member]                                    
Loss Contingencies [Line Items]                                    
Purchase agreement description     As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.                              
License Agreement [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty expense $ 50,000                                  
Outstanding units percentage   10.00%                                
License Agreement [Member] | Royalty Agreement Terms [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty expense $ 100,000                                  
License Agreement [Member] | Minimum [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty expense percentage   1.50%                                
License Agreement [Member] | Maximum [Member]                                    
Loss Contingencies [Line Items]                                    
Royalty expense percentage   3.00%